Company Overview - Yifang Biotechnology (Shanghai) Co., Ltd. is located in the China (Shanghai) Free Trade Zone and was established on January 11, 2013. The company went public on July 25, 2022. Its main business involves the research, production, and sales of innovative drugs, with 100% of its revenue coming from technology licensing and cooperation [1]. Stock Performance - On September 26, Yifang Biotechnology's stock fell by 5.09%, trading at 31.70 CNY per share, with a transaction volume of 134 million CNY and a turnover rate of 1.00%. The company's total market capitalization is 18.333 billion CNY [1]. Fund Holdings - According to data from major funds, Guolian Fund has a significant holding in Yifang Biotechnology. The Guolian Medical Consumption Mixed A Fund (015032) reduced its holdings by 71,100 shares in the second quarter, retaining 152,100 shares, which accounts for 5.93% of the fund's net value, making it the third-largest holding. The estimated floating loss today is approximately 258,600 CNY [2]. Fund Performance - The Guolian Medical Consumption Mixed A Fund (015032) was established on March 9, 2022, with a latest scale of 33.0955 million CNY. Year-to-date, it has achieved a return of 57.31%, ranking 816 out of 8,171 in its category. Over the past year, it has returned 82.14%, ranking 1,091 out of 8,004. Since inception, the fund has returned 11.96% [2]. Fund Management - The fund manager of Guolian Medical Consumption Mixed A Fund (015032) is Pan Tianqi, who has been in the position for 5 years and 178 days. The total asset size of the fund is 84.1388 million CNY, with the best return during his tenure being 8% and the worst being -0.27% [3].

Core Insights - Guolian Pharmaceutical Consumption Mixed A (015032) has experienced a decline of 1.35% on June 19, with a latest net value of 0.9 yuan, marking a cumulative drop of 7.36% over five consecutive trading days [1] - The fund was established in March 2022 with a total size of 0.28 billion yuan and has recorded a cumulative return of -9.51% since inception [1] - As of the end of 2024, institutional investors hold 0.04 billion shares, accounting for 12.38% of total shares, while individual investors hold 0.32 billion shares, making up 87.62% of total shares [1] Fund Manager Profile - The current fund manager, Mr. Pan Tianqi, holds a Bachelor of Science from Sichuan University, a Master of Science from the University of Pittsburgh, and an MBA from Katz Graduate School of Business [1] - Mr. Pan has previously worked as a researcher at Heng Rui Medicine Co., Ltd., and as a senior researcher and assistant fund manager at Guotai Junan Fund Management Co., Ltd. [1] - He joined He Xu Zhi Yuan Fund Management Co., Ltd. in July 2018 and has held various managerial positions, including the fund manager of the Zhongrong Pharmaceutical Consumption Mixed Securities Investment Fund since June 14, 2022 [1] Top Holdings - As of March 31, 2025, the top ten holdings of Guolian Pharmaceutical Consumption Mixed A account for a total of 48.85%, with significant positions in Heng Rui Medicine (7.78%), Zai Lab (6.18%), and BeiGene (4.69%) [2] - Other notable holdings include Haoyuan Pharmaceutical (4.50%), Aosaikang (4.45%), and Nocera Health (4.36%) [2] - The fund also holds shares in Guizhou Moutai (4.35%), Dize Pharmaceutical (4.31%), Yifang Bio (4.25%), and United Imaging Healthcare (3.98%) [2]